Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 3/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.45 |
| ▸ | XDH | P47989 | 12/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 12/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21311941 | 0.86 | FYN (0.52) | FYNXDHSLC22A12BRAFCYP3A4 | |
| SCHEMBL4189117 | 0.85 | XDH (0.47) | XDHSLC22A12 | |
| SCHEMBL4154890 | 0.85 | XDH (0.60) | FYNXDHSLC22A12 | |
| SCHEMBL4194358 | 0.83 | XDH (0.60) | FYNXDHSLC22A12BRAFTP53 | |
| SCHEMBL4187619 | 0.83 | BRAF (0.62) | FYNCYP17A1XDHSLC22A12BRAF | |
| SCHEMBL21311940 | 0.82 | FYN (0.53) | FYNXDHSLC22A12BRAFTP53 | |
| SCHEMBL4143146 | 0.82 | XDH (0.62) | FYNXDHSLC22A12BRAFGAA | |
| SCHEMBL4164292 | 0.80 | HSD17B1 (0.54) | FYNCYP17A1XDHSLC22A12ALDH1A1 | |
| SCHEMBL4183096 | 0.79 | ABCG2 (0.52) | FYNXDHSLC22A12 | |
| SCHEMBL4194098 | 0.77 | XDH (0.64) | FYNXDHSLC22A12TP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | claimed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | disclosed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | FYN 3292/4885CYP17A1 468/4885XDH 1630/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | FYN 3292/4885CYP17A1 468/4885XDH 1630/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | FYN 3292/4885CYP17A1 468/4885XDH 1630/4885 |
| US-20090196912-A1 | Pyridinylamines | PRNP, PLPBP, SNCA | FYN 173/4885CYP17A1 1120/4885XDH 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.